Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold

Meperidine administration is a more effective treatment for shivering than equianalgesic doses of other opioids. However, it remains unknown whether meperidine also profoundly impairs other thermoregulatory responses, such as sweating or vasoconstriction. Proportional inhibition of vasoconstriction...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anesthesiology (Philadelphia) 1997-05, Vol.86 (5), p.1046-1054
Hauptverfasser: KURZ, A, IKEDA, T, SESSLER, D. I, LARSON, M. D, BJORKSTEN, A. R, DECHERT, M, CHRISTENSEN, R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1054
container_issue 5
container_start_page 1046
container_title Anesthesiology (Philadelphia)
container_volume 86
creator KURZ, A
IKEDA, T
SESSLER, D. I
LARSON, M. D
BJORKSTEN, A. R
DECHERT, M
CHRISTENSEN, R
description Meperidine administration is a more effective treatment for shivering than equianalgesic doses of other opioids. However, it remains unknown whether meperidine also profoundly impairs other thermoregulatory responses, such as sweating or vasoconstriction. Proportional inhibition of vasoconstriction and shivering suggests that the drug acts much like alfentanil and anesthetics but possesses greater thermoregulatory than analgesic potency. In contrast, disproportionate inhibition would imply a special antishivering mechanism. Accordingly, the authors tested the hypothesis that meperidine administration produces a far greater concentration-dependent reduction in the shivering than vasoconstriction threshold. Nine volunteers were each studied on three days: 1) control (no opioid); 2) a target total plasma meperidine concentration of 0.6 microgram/ml (40 mg/h); and 3) a target concentration of 1.8 micrograms/ml (120 mg/h). Each day, skin and core temperatures were increased to provoke sweating and then subsequently reduced to elicit vasoconstriction and shivering. Core-temperature thresholds (at a designated skin temperature of 34 degrees C) were computed using established linear cutaneous contributions to control sweating (10%) and vasoconstriction and shivering (20%). The dose-dependent effects of unbound meperidine on thermoregulatory response thresholds was then determined using linear regression. Results are presented as means +/- SDs. The unbound meperidine fraction was approximately 35%. Meperidine administration slightly increased the sweating threshold (0.5 +/- 0.8 degree C.microgram-1.ml; r2 = 0.51 +/- 0.37) and markedly decreased the vasoconstriction threshold (-3.3 +/- 1.5 degrees C.microgram-1.ml; r2 = 0.92 +/- 0.08). However, meperidine reduced the shivering threshold nearly twice as much as the vasoconstriction threshold (-6.1 +/- 3.0 degrees C.microgram-1.ml; r2 = 0.97 +/- 0.05; P = 0.001). The special antishivering efficacy of meperidine results at least in part from an uncharacteristically large reduction in the shivering threshold rather than from exaggerated generalized thermoregulatory inhibition. This pattern of thermoregulatory impairment differs from that produced by alfentanil, clonidine, propofol, and the volatile anesthetics, all which reduce the vasoconstriction and shivering thresholds comparably.
doi_str_mv 10.1097/00000542-199705000-00007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79006531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79006531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-dc4019b3da0861ea428e8f4e7fa49b2afd5b151826bf5034e323c5574520e19a3</originalsourceid><addsrcrecordid>eNpFkE1Pg0AQhjdGU2v1J5hwMN7Q_WBYOJrGr6TGi95MyLIMsoZC3YEa_71gsc5lMu_7zEzyMhYIfiV4qq_5WBDJUKSp5jAM4ajoAzYXIJNQCA2HbD5IKlRcymN2QvQxEqCSGZulAhIFas7ennCD3hWuwaBA69EQUtBVGFDltoPTvA-TR6raugi6L2cxMBSse1uNfQS3hlrbNtR5ZzvXNv_8KTsqTU14NvUFe727fVk-hKvn-8flzSq0EUAXFjbiIs1VYXgSCzSRTDApI9SlidJcmrKAXIBIZJyXwFWESioLoCOQHEVq1IJd7u5ufPvZI3XZ2pHFujYNtj1lOuU8BiUGMNmB1rdEHsts493a-O9M8GwMNvsLNtsH-yvpYfV8-tHnayz2i1OSg38x-YasqUtvGutoj8kYYqVj9QMOU4EK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79006531</pqid></control><display><type>article</type><title>Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>KURZ, A ; IKEDA, T ; SESSLER, D. I ; LARSON, M. D ; BJORKSTEN, A. R ; DECHERT, M ; CHRISTENSEN, R</creator><creatorcontrib>KURZ, A ; IKEDA, T ; SESSLER, D. I ; LARSON, M. D ; BJORKSTEN, A. R ; DECHERT, M ; CHRISTENSEN, R</creatorcontrib><description>Meperidine administration is a more effective treatment for shivering than equianalgesic doses of other opioids. However, it remains unknown whether meperidine also profoundly impairs other thermoregulatory responses, such as sweating or vasoconstriction. Proportional inhibition of vasoconstriction and shivering suggests that the drug acts much like alfentanil and anesthetics but possesses greater thermoregulatory than analgesic potency. In contrast, disproportionate inhibition would imply a special antishivering mechanism. Accordingly, the authors tested the hypothesis that meperidine administration produces a far greater concentration-dependent reduction in the shivering than vasoconstriction threshold. Nine volunteers were each studied on three days: 1) control (no opioid); 2) a target total plasma meperidine concentration of 0.6 microgram/ml (40 mg/h); and 3) a target concentration of 1.8 micrograms/ml (120 mg/h). Each day, skin and core temperatures were increased to provoke sweating and then subsequently reduced to elicit vasoconstriction and shivering. Core-temperature thresholds (at a designated skin temperature of 34 degrees C) were computed using established linear cutaneous contributions to control sweating (10%) and vasoconstriction and shivering (20%). The dose-dependent effects of unbound meperidine on thermoregulatory response thresholds was then determined using linear regression. Results are presented as means +/- SDs. The unbound meperidine fraction was approximately 35%. Meperidine administration slightly increased the sweating threshold (0.5 +/- 0.8 degree C.microgram-1.ml; r2 = 0.51 +/- 0.37) and markedly decreased the vasoconstriction threshold (-3.3 +/- 1.5 degrees C.microgram-1.ml; r2 = 0.92 +/- 0.08). However, meperidine reduced the shivering threshold nearly twice as much as the vasoconstriction threshold (-6.1 +/- 3.0 degrees C.microgram-1.ml; r2 = 0.97 +/- 0.05; P = 0.001). The special antishivering efficacy of meperidine results at least in part from an uncharacteristically large reduction in the shivering threshold rather than from exaggerated generalized thermoregulatory inhibition. This pattern of thermoregulatory impairment differs from that produced by alfentanil, clonidine, propofol, and the volatile anesthetics, all which reduce the vasoconstriction and shivering thresholds comparably.</description><identifier>ISSN: 0003-3022</identifier><identifier>EISSN: 1528-1175</identifier><identifier>DOI: 10.1097/00000542-199705000-00007</identifier><identifier>PMID: 9158353</identifier><identifier>CODEN: ANESAV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Alfentanil - pharmacology ; Analgesics ; Analgesics, Opioid - blood ; Analgesics, Opioid - pharmacology ; Biological and medical sciences ; Humans ; Male ; Medical sciences ; Meperidine - blood ; Meperidine - pharmacology ; Neuropharmacology ; Pharmacology. Drug treatments ; Shivering - drug effects ; Shivering - physiology ; Skin Temperature - drug effects ; Vasoconstriction - drug effects</subject><ispartof>Anesthesiology (Philadelphia), 1997-05, Vol.86 (5), p.1046-1054</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-dc4019b3da0861ea428e8f4e7fa49b2afd5b151826bf5034e323c5574520e19a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2656376$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9158353$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KURZ, A</creatorcontrib><creatorcontrib>IKEDA, T</creatorcontrib><creatorcontrib>SESSLER, D. I</creatorcontrib><creatorcontrib>LARSON, M. D</creatorcontrib><creatorcontrib>BJORKSTEN, A. R</creatorcontrib><creatorcontrib>DECHERT, M</creatorcontrib><creatorcontrib>CHRISTENSEN, R</creatorcontrib><title>Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold</title><title>Anesthesiology (Philadelphia)</title><addtitle>Anesthesiology</addtitle><description>Meperidine administration is a more effective treatment for shivering than equianalgesic doses of other opioids. However, it remains unknown whether meperidine also profoundly impairs other thermoregulatory responses, such as sweating or vasoconstriction. Proportional inhibition of vasoconstriction and shivering suggests that the drug acts much like alfentanil and anesthetics but possesses greater thermoregulatory than analgesic potency. In contrast, disproportionate inhibition would imply a special antishivering mechanism. Accordingly, the authors tested the hypothesis that meperidine administration produces a far greater concentration-dependent reduction in the shivering than vasoconstriction threshold. Nine volunteers were each studied on three days: 1) control (no opioid); 2) a target total plasma meperidine concentration of 0.6 microgram/ml (40 mg/h); and 3) a target concentration of 1.8 micrograms/ml (120 mg/h). Each day, skin and core temperatures were increased to provoke sweating and then subsequently reduced to elicit vasoconstriction and shivering. Core-temperature thresholds (at a designated skin temperature of 34 degrees C) were computed using established linear cutaneous contributions to control sweating (10%) and vasoconstriction and shivering (20%). The dose-dependent effects of unbound meperidine on thermoregulatory response thresholds was then determined using linear regression. Results are presented as means +/- SDs. The unbound meperidine fraction was approximately 35%. Meperidine administration slightly increased the sweating threshold (0.5 +/- 0.8 degree C.microgram-1.ml; r2 = 0.51 +/- 0.37) and markedly decreased the vasoconstriction threshold (-3.3 +/- 1.5 degrees C.microgram-1.ml; r2 = 0.92 +/- 0.08). However, meperidine reduced the shivering threshold nearly twice as much as the vasoconstriction threshold (-6.1 +/- 3.0 degrees C.microgram-1.ml; r2 = 0.97 +/- 0.05; P = 0.001). The special antishivering efficacy of meperidine results at least in part from an uncharacteristically large reduction in the shivering threshold rather than from exaggerated generalized thermoregulatory inhibition. This pattern of thermoregulatory impairment differs from that produced by alfentanil, clonidine, propofol, and the volatile anesthetics, all which reduce the vasoconstriction and shivering thresholds comparably.</description><subject>Alfentanil - pharmacology</subject><subject>Analgesics</subject><subject>Analgesics, Opioid - blood</subject><subject>Analgesics, Opioid - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Meperidine - blood</subject><subject>Meperidine - pharmacology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Shivering - drug effects</subject><subject>Shivering - physiology</subject><subject>Skin Temperature - drug effects</subject><subject>Vasoconstriction - drug effects</subject><issn>0003-3022</issn><issn>1528-1175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Pg0AQhjdGU2v1J5hwMN7Q_WBYOJrGr6TGi95MyLIMsoZC3YEa_71gsc5lMu_7zEzyMhYIfiV4qq_5WBDJUKSp5jAM4ajoAzYXIJNQCA2HbD5IKlRcymN2QvQxEqCSGZulAhIFas7ennCD3hWuwaBA69EQUtBVGFDltoPTvA-TR6raugi6L2cxMBSse1uNfQS3hlrbNtR5ZzvXNv_8KTsqTU14NvUFe727fVk-hKvn-8flzSq0EUAXFjbiIs1VYXgSCzSRTDApI9SlidJcmrKAXIBIZJyXwFWESioLoCOQHEVq1IJd7u5ufPvZI3XZ2pHFujYNtj1lOuU8BiUGMNmB1rdEHsts493a-O9M8GwMNvsLNtsH-yvpYfV8-tHnayz2i1OSg38x-YasqUtvGutoj8kYYqVj9QMOU4EK</recordid><startdate>19970501</startdate><enddate>19970501</enddate><creator>KURZ, A</creator><creator>IKEDA, T</creator><creator>SESSLER, D. I</creator><creator>LARSON, M. D</creator><creator>BJORKSTEN, A. R</creator><creator>DECHERT, M</creator><creator>CHRISTENSEN, R</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970501</creationdate><title>Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold</title><author>KURZ, A ; IKEDA, T ; SESSLER, D. I ; LARSON, M. D ; BJORKSTEN, A. R ; DECHERT, M ; CHRISTENSEN, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-dc4019b3da0861ea428e8f4e7fa49b2afd5b151826bf5034e323c5574520e19a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Alfentanil - pharmacology</topic><topic>Analgesics</topic><topic>Analgesics, Opioid - blood</topic><topic>Analgesics, Opioid - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Meperidine - blood</topic><topic>Meperidine - pharmacology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Shivering - drug effects</topic><topic>Shivering - physiology</topic><topic>Skin Temperature - drug effects</topic><topic>Vasoconstriction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KURZ, A</creatorcontrib><creatorcontrib>IKEDA, T</creatorcontrib><creatorcontrib>SESSLER, D. I</creatorcontrib><creatorcontrib>LARSON, M. D</creatorcontrib><creatorcontrib>BJORKSTEN, A. R</creatorcontrib><creatorcontrib>DECHERT, M</creatorcontrib><creatorcontrib>CHRISTENSEN, R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anesthesiology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KURZ, A</au><au>IKEDA, T</au><au>SESSLER, D. I</au><au>LARSON, M. D</au><au>BJORKSTEN, A. R</au><au>DECHERT, M</au><au>CHRISTENSEN, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold</atitle><jtitle>Anesthesiology (Philadelphia)</jtitle><addtitle>Anesthesiology</addtitle><date>1997-05-01</date><risdate>1997</risdate><volume>86</volume><issue>5</issue><spage>1046</spage><epage>1054</epage><pages>1046-1054</pages><issn>0003-3022</issn><eissn>1528-1175</eissn><coden>ANESAV</coden><abstract>Meperidine administration is a more effective treatment for shivering than equianalgesic doses of other opioids. However, it remains unknown whether meperidine also profoundly impairs other thermoregulatory responses, such as sweating or vasoconstriction. Proportional inhibition of vasoconstriction and shivering suggests that the drug acts much like alfentanil and anesthetics but possesses greater thermoregulatory than analgesic potency. In contrast, disproportionate inhibition would imply a special antishivering mechanism. Accordingly, the authors tested the hypothesis that meperidine administration produces a far greater concentration-dependent reduction in the shivering than vasoconstriction threshold. Nine volunteers were each studied on three days: 1) control (no opioid); 2) a target total plasma meperidine concentration of 0.6 microgram/ml (40 mg/h); and 3) a target concentration of 1.8 micrograms/ml (120 mg/h). Each day, skin and core temperatures were increased to provoke sweating and then subsequently reduced to elicit vasoconstriction and shivering. Core-temperature thresholds (at a designated skin temperature of 34 degrees C) were computed using established linear cutaneous contributions to control sweating (10%) and vasoconstriction and shivering (20%). The dose-dependent effects of unbound meperidine on thermoregulatory response thresholds was then determined using linear regression. Results are presented as means +/- SDs. The unbound meperidine fraction was approximately 35%. Meperidine administration slightly increased the sweating threshold (0.5 +/- 0.8 degree C.microgram-1.ml; r2 = 0.51 +/- 0.37) and markedly decreased the vasoconstriction threshold (-3.3 +/- 1.5 degrees C.microgram-1.ml; r2 = 0.92 +/- 0.08). However, meperidine reduced the shivering threshold nearly twice as much as the vasoconstriction threshold (-6.1 +/- 3.0 degrees C.microgram-1.ml; r2 = 0.97 +/- 0.05; P = 0.001). The special antishivering efficacy of meperidine results at least in part from an uncharacteristically large reduction in the shivering threshold rather than from exaggerated generalized thermoregulatory inhibition. This pattern of thermoregulatory impairment differs from that produced by alfentanil, clonidine, propofol, and the volatile anesthetics, all which reduce the vasoconstriction and shivering thresholds comparably.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>9158353</pmid><doi>10.1097/00000542-199705000-00007</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-3022
ispartof Anesthesiology (Philadelphia), 1997-05, Vol.86 (5), p.1046-1054
issn 0003-3022
1528-1175
language eng
recordid cdi_proquest_miscellaneous_79006531
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Alfentanil - pharmacology
Analgesics
Analgesics, Opioid - blood
Analgesics, Opioid - pharmacology
Biological and medical sciences
Humans
Male
Medical sciences
Meperidine - blood
Meperidine - pharmacology
Neuropharmacology
Pharmacology. Drug treatments
Shivering - drug effects
Shivering - physiology
Skin Temperature - drug effects
Vasoconstriction - drug effects
title Meperidine decreases the shivering threshold twice as much as the vasoconstriction threshold
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T02%3A45%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meperidine%20decreases%20the%20shivering%20threshold%20twice%20as%20much%20as%20the%20vasoconstriction%20threshold&rft.jtitle=Anesthesiology%20(Philadelphia)&rft.au=KURZ,%20A&rft.date=1997-05-01&rft.volume=86&rft.issue=5&rft.spage=1046&rft.epage=1054&rft.pages=1046-1054&rft.issn=0003-3022&rft.eissn=1528-1175&rft.coden=ANESAV&rft_id=info:doi/10.1097/00000542-199705000-00007&rft_dat=%3Cproquest_cross%3E79006531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79006531&rft_id=info:pmid/9158353&rfr_iscdi=true